[1] Di J,Rutherford S,Chu C.Review of the cervical cancer burden and population-based cervical cancer screening in China[J].Asi- an Pac J Cancer Prev,2015,16( 17) : 7401-7407. [2] Shi JF,Qiao YL,Smith JS,et al.Epidemiology and prevention of human papillomavirus and cervical cancer in China and Mongolia [J]. Vaccine,2008,26 Suppl: M53-59. [3] Bray F,Ren JS,Masuyer E,et al.Global estimates of cancer prevalence for 27 sites in the adult population in 2008 [J].Int J Cancer,2013,132( 5) : 1133-1145.[4]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics2018:Globocan estimates of incidence and mortality worldwidefor 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.[5] Ferlay J,Colombet M,Soerjomataram I,et al. Estimating theglobal cancer incidence and mortality in 2018:Globocan sourc⁃es and methods[J].Int J Cancer,2019,144(8):1941-1953.[6] 刘萍.中国大陆13年宫颈癌临床流行病学大数据评价[J].中国实用妇科与产科杂志,2018,34(1):41-45.[7]Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30 Suppl 5:F12.
[8]de Sanjosé S, Alemany L, Ordi J, et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer 2013; 49:3450.
[9]De Vuyst H, Clifford GM, Nascimento MC, et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009; 124:1626.
[10]Chao A, Jao MS, Huang CC, et al. Human papillomavirus genotype in cervical intraepithelial neoplasia grades 2 and 3 of Taiwanese women. Int J Cancer 2011; 128:653.
[11]Smith JS, Backes DM, Hoots BE, et al. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet Gynecol 2009; 113:917.
[12] International Agency f or Research on Cancer. Human papillomavirus and related diseases in the world [R]. Lyon: IARC, 2019. [13] ZHAO FH, ADAM KL, HU SY, et al. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies [J]. Int J Cancer, 2012, 131(12): 2929-2938. DOI: 10. 1002/ijc. 27571. [14] WRIGHT TC. Natural history of HPV infections [J]. J Fam Pract, 2009, 58(Suppl 9): S3-7. [15] HISHAM M, TOM B, TOM A, et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta analysis of trends by time and region [J]. Head & Neck, 2012, 35(5): 747-755. DOI: 10. 1002/hed. 22015. [16] MU NOZ N, BOSCH FX, CASTELLSAG UE X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective [J]. International Journal of Cancer, 2004, 111(2): 278-285. DOI: 10. 1002/ijc. 20244.[17] ZUNA ER, ALLEN AR MOORE EW, et al. Distribution of HPV genot y pes in 282 women wit h cer vical lesions: evidence for three categories of intraepithelial lesions based on mor pholog y a nd HPV t y pe [J]. Modern Pathology, 2006, 20(2): 167-174. DOI: 10. 1038/modpathol. 3800723. [18] GRAVITT PE. The known unknowns of HPV natural history [J]. The Journal of Clinical Investigation, 2011, 121(12): 4593-4599. DOI: 10. 1172/JCI57149. [19]Freedman M, Kroger A, Hunter P, et al. Recommended Adult Immunization Schedule, United States, 2020. Ann Intern Med 2020; 172:337.
[20]Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63:1.
[21]Petrosky E, Bocchini JA Jr, Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 2015; 64:300.
[22]Robinson CL, Bernstein H, Poehling K, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2020. MMWR Morb Mortal Wkly Rep 2020; 69:130.
[23]Meites E, Szilagyi PG, Chesson HW, et al. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2019; 68:698.
[24]Human Papillomavirus Vaccination Coverage Among Adolescent Girls, 2007–2012, and Postlicensure Vaccine Safety Monitoring, 2006–2013 — United States. MMWR Recomm Rep 2013; 62:591.
[25]Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009; 302:750.
[26] CHEN W, MOLIJ N A, ENQI W, et al. The variable clinicopathological categories and role of human papillomavirus in cervical adenocarcinoma: a hospital based nation-wide multi-center retrospective study across China [J]. Int J Cancer, 2016, 139(12): 2687-2697. DOI: 10. 1002/ijc. 30401.
[27] CHEN W, ZHANG X, MOLIJN A, et al. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18 [J]. Cancer Causes Control, 2009, 20(9): 1705-1713. DOI: 10. 1007/s10552-009-9422-z.